Treat-to-target strategy in gout management is effective

October 18, 2018

(Boston)--Gout is the most common form of inflammatory arthritis, caused by crystallization of uric acid in the joint. Rheumatologists have long recommended that patients with gout be treated with drugs to lower uric acid in their blood to prevent crystallization. Specifically, rheumatology societies around the world recommend that uric acid should be lowered to below 6mg/dL because that's below the concentration at which uric acid can crystalize. This strategy is known as "treat-to-target."

Recently, controversy about this recommendation was raised because the American College of Physicians' guidelines stated that there were insufficient data to support a treat-to-target strategy, and that a strategy of treating to avoid symptoms may be reasonable.

In a randomized controlled trial published in the Lancet, nurse-led care that included education and engagement of patients as well as a treat-to-target strategy to lower uric acid was compared with usual care by general practitioners (GP). In this trial, the nurse-led care group had more than a three-fold higher achievement of lowering uric acid to below 6mg/dL, had 67 percent lower risk of gout flares and 79 percent lower risk of having any tophi at the end of follow-up at two years compared with usual care. Further, the nurse-led care strategy was projected to be cost saving by five years.

An accompanying Lancet comment led by Tuhina Neogi, MD, PhD, professor of medicine and epidemiology at Boston University Schools of Medicine and Public Health, noted that this trial adds to a growing body of evidence that the treat-to-target strategy in gout management is effective and there is now ample data from randomized trials to support this treatment approach.

"The high adherence, combined with use of higher doses of allopurinol in the nurse-led group contributed to the marked beneficial effects experienced in the nurse-led group. The findings highlight that patients can adhere to treatment when they receive the appropriate information about their disease, adequate support by their healthcare provider with regular follow-up and feedback," said Neogi.

According to the authors, this trial provides definitive evidence that a treat-to-target strategy in gout results in better patient outcomes than the usual care provided by GPs. "While GPs may not have the capacity to see their patients with gout more frequently, other health care professionals can be trained to implement this approach as has been done in other diseases," she explained. "Highly efficacious and cost-effective gout management can be readily achieved by educating and spending time with patients. Patients with gout can get their disease under control using a treat-to-target approach. This should now be the standard of care for gout management."
Nicola Dalbeth, MBChB, MD, FRACP, from the Department of Medicine, University of Auckland, Auckland, New Zealand, also contributed to this editorial.


TN is involved in a clinical trial of febuxostat compared with allopurinol in gout as a steering committee member funded by a grant from the US Department of Veterans Affairs (VA CSP-594) and the National Institutes of Health.

ND has received grants from Amgen, grants and personal fees from AstraZeneca, and personal fees from AbbVie, Horizon, Takeda, Kowa, Janssen, and Pfizer. ND is supported by the Health Research Council of New Zealand (15/576). In the past 5 years, she has been principal investigator on a clinical trial of febuxostat in early gout (funded by Takeda) and a clinical trial of lesinurad and febuxostat (funded by AstraZeneca) and co-investigator on a clinical trial of allopurinol dose escalation (funded by the Health Research Council of New Zealand).

Boston University School of Medicine

Related Gout Articles from Brightsurf:

Gout drug repurposed to fight heart disease
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.1 ''Over a decade, more than one in three heart patients will have another heart attack or stroke, or die from heart disease, despite taking preventive medication,'' said study author Dr.

Gout treatment may aid patients with congenital heart disease
A drug used to treat gout, probenecid, may improve heart function in individuals with a particular heart defect, according to results from a small pilot study run by a University of Cincinnati researcher.

EULAR: Amputations of body parts: The combination of diabetes and gout significantly increases
Compared to the average population, people suffering from both gout and diabetes have a 25 times higher risk of requiring an amputation of peripheral limbs such as feet, toes or lower legs.

Gout diagnoses rising worldwide
The prevalence of gout -- a form of arthritis characterized by severe pain, redness, and tenderness in joints--increased across the world at an alarming rate from 1990 to 2017, according to an analysis published in Arthritis & Rheumatology.

ACR releases gout management guideline
Today, the American College of Rheumatology (ACR) released the 2020 Guideline for the Management of Gout.

New optical biosensor system may help round-the-clock management of gout
In a recent article published in the February issue of the journal sensors, researchers at Texas A&M University have reported a technology that might help people with gout disease monitor their symptoms better.

Blood pressure drug linked to lower risk of gout
A new study led by physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) reports that the antihypertensive drug amlodipine lowered long-term gout risk compared to two other drugs commonly prescribed to lower blood pressure.

Wearable sweat sensor detects gout-causing compounds
Caltech's Wei Gao has developed an easier way to mass-produce highly sensitive sweat sensors that can detect a variety of low-concentration compounds related to health conditions

WSU study identifies potential new target for treatment of gout
Researchers at Washington State University Health Sciences Spokane and elsewhere have identified a new therapeutic target for the treatment of gout, a common type of arthritis that causes episodes of painful and stiff joints.

Heart, kidney disease risk factors for adverse effects from gout medication
Heart disease is an independent risk factor for severe adverse skin reactions in patients taking allopurinol, found a study published in CMAJ (Canadian Medical Association Journal).

Read More: Gout News and Gout Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to